1. Qualified method for the estimation of di-18:1 bis(monoacylglycero)phosphate in urine, a noninvasive biomarker to monitor drug-induced phospholipidosis.
- Author
-
Murali BV, Kurawattimath V, Bhutani P, Onorato J, Naikodi SB, Kole P, and Rajanna PK
- Subjects
- Animals, Humans, Lysosomal Storage Diseases urine, Male, Rats, Rats, Sprague-Dawley, Sphingolipidoses urine, Biomarkers urine, Chromatography, Liquid methods, Lysophospholipids urine, Lysosomal Storage Diseases chemically induced, Monoglycerides urine, Phospholipids metabolism, Sphingolipidoses chemically induced, Tandem Mass Spectrometry methods
- Abstract
Aim: Our objective was to develop and qualify a bioanalytical method for the estimation of di-18:1-bis(monoacylglycero)phosphate (di-18:1 BMP) as a urinary biomarker for the assessment of drug-induced phospholipidosis and demonstrate its application in a preclinical study. Methodology/results: di-18:1 BMP was extracted by liquid-liquid extraction using n-butanol and analyzed by LC-MS/MS. The qualified method was selective, precise, robust and accurate across the linearity range (0.2-250 ng/ml). Qualified method was then used to assess chloroquine-induced phospholipidosis in rats dosed at 120 mg/kg for 5 days. A fivefold increase in di-18:1 BMP was observed on Day 5 compared with predose. Conclusion: Di-18:1 BMP can be used as a noninvasive biomarker to assess/screen compounds that could cause drug-induced phospholipidosis in rats.
- Published
- 2020
- Full Text
- View/download PDF